Navigation Links
Isis Pharmaceuticals Announces Its Participation at the Upcoming,ACC 56th Annual Scientific Session in New Orleans and Its Live,Analyst/Investor Webcast Presentation

CARLSBAD, Calif., March 22, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals announces that results from three Phase 2 studies of ISIS 301012, including effects of ISIS 301012 in homozygous familial hypercholesterolemic (HoFH) patients, will be the subjects of three upcoming presentations at the of Cardiology (ACC), March 24-27 in New Orleans. Planned presentations include effects of ISIS 301012 in patients both as monotherapy and added to stable statin therapy. An overall summary of the Phase 2 program results for ISIS 301012 will be provided at the March 27 Analyst/Investor webcast presentation, along with a summary of Isis' development plan for ISIS 301012. ISIS 301012 is the Company's cholesterol-lowering drug targeting apoB-100.

    Sunday, March 25, 2007


    Session:          1206:  Vascular Disease, Hypertension and Prevention --

                      V-cast Poster


    Track:            ACC.Vascular Disease, Hypertension, and Prevention


    Room:             Hall H


    Presentation:     1206-278


    Abstract:         Statin-Like, Dose-Dependent Reductions in LDL-C and

                      Apolipoprotein B With ISIS 301012, an Antisense

                      Inhibitor of Apolipoprotein B, in Subjects With

                      Polygenic Hypercholesterolemia


    Monday, March 26, 2007


    Session:          603:  Common Challenges in Preventive Cardiology

                      (7:00 - 8:30 a.m. CT)


    Track:            ACC.Symposium


    Room:             Auditorium B


    Presentation:     603-8


    Time:             8:15 - 8:30 a.m.


    Speaker:          Dr. Evan A. Stein


    Title:            High Low-Density Lipoprotein Cholesterol on Three Drugs*

                      *to include preliminary results of an ongoing study

                      evaluating ISIS 301012 in HoFH patients on concurrent

                      maximally tolerated lipid-lowering therapies


    Session:          820:  Clinical Trials of 
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:9/19/2014)... TRIANGLE PARK, N.C. , Sept. 19, 2014 ... focused on cloud-based drug design and development, partnering ... The company,s mission is to design new drugs ... 1 and 2 partners to further their development. ... its portfolio investments. To support this business model, ...
(Date:9/19/2014)... Research and Markets has announced the addition of ... Mental Disorder) Market - Forecast to 2023" report to ... the human microbiome market is segmented by application, disease, product, ... to be valued as $294 million in 2019 and is ... forecast period of 2019-2023. The market is driven by growing ...
(Date:9/19/2014)... WASHINGTON , Sept. 19, 2014 The ... that Drive Medical Design and Manufacturing has joined the ... its CEO Harvey Diamond have been actively ... year history, as it has quickly grown into a ... corporate partners like Drive allows AAHomecare to increase efforts ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Laser,Centers, the largest provider of laser hair removal ... the addition of the VelaShape,cellulite reduction and body ... 30 additional locations before the end of March, ... FDA-approved for both cellulite,reduction and circumferential reduction of ...
... has,received its third $10 million tranche of equity funding ... milestones:,validating the efficacy and safety of its two topical ... influenza vaccine in,ferret studies., The company, a spin-off ... $30 million over the past 18 months from Perseus ...
Cached Medicine Technology:American Laser Center Offers VelaShape Body Shaping and Cellulite Reduction Treatment 2NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2
(Date:9/19/2014)... -- As kids transition from elementary to middle school, ... a recent study. But the researchers studying ... verbal and physical bullying declines as students get older. ... strategies must address all types of bullying as well ... researchers said. The study was published recently in ...
(Date:9/19/2014)... 9/18/14) A leading Dartmouth researcher, working with The Melanoma ... paper published today in the Journal of the ... the risk of melanoma. , "For the first time, ... of these telomeres play a part in the risk ... Mark Iles, PhD, School of Medicine at the University ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- U.S. military ... risk of skin cancer, according to a new study. ... serving abroad, researchers revealed. In some cases, military personnel ... in the color, shape or size of their moles ... can be risk factors for skin cancer, the study ...
(Date:9/19/2014)... FRIDAY, Sept. 19, 2014 (HealthDay News) -- The U.S. Food ... Trulicity, on Thursday. Trulicity is part of a class of ... adults with type 2 diabetes. "Trulicity is a ... to existing treatment regimens to control blood sugar levels in ... deputy director of the FDA,s Office of Drug Evaluation II, ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 MetroMD, a leading ... the “God Particle” of human health. This therapy has grown ... making the therapy more effective, safe and dependable. It has ... them an opportunity to live a very healthy and active ... concept of HGH therapy, a senior therapist at MetroMD said, ...
Breaking Medicine News(10 mins):Health News: Cyberbullying Seems to Ramp Up in Middle School 2Health News:Melanoma risk found to have genetic determinant 2Health News:Some U.S. Troops May Face Greater Skin Cancer Risk 2Health News:FDA Approves Another Weekly Injectable Drug for Type 2 Diabetes 2Health News:MetroMD Announces Better HGH Therapy - the ‘God Particle’ of Human Health 2
... 6 Cowen Group, Inc. (Nasdaq: COWN ) ... a Senior Analyst covering managed care and health care service ... covered health care services stocks from 1999 to 2008. ... the lead analyst covering healthcare services. Between 2000 and ...
... 6 Prism Pharmaceuticals, Inc.,announced today that Dr. Warren ... the 27th Annual J.P. Morgan Healthcare Conference on,Tuesday, January ... a.m. (Eastern,Time). The conference will be held at ... Dr. Cooper will present corporate ...
... SMTS ) will release its financial results for ... before the opening of the market on,Wednesday, January 21, ... will host a conference call that will be webcast ... On the conference call, Bruce Barrett, ...
... at Home Depot saw big increase in employees working out ... to work out works, a new study says. , ... to support workers in setting exercise goals notably increased their ... The findings were published in the February edition of ...
... Design Creates Tangible Value by Revealing New Revenue ... LLC, a firm that specializes in designing customer-centric ... for growth-oriented companies, today announced its official launch. ... build and launch new services around business opportunities ...
... Population is Undertreated When Compared to California, According ... Mass., Jan. 6 Decision Resources, one of ... on pharmaceutical and healthcare issues, finds that Florida ... the Alzheimer,s disease drug market despite the large ...
Cached Medicine News:Health News:Cowen Adds Health Care Service Analyst to Equity Research Department 2Health News:Somanetics Corporation to Release Fourth Quarter and Fiscal 2008 Financial Results and Host Conference Call January 21, 2009 2Health News:Employer-Sponsored Workouts Boost Workers' Health 2Health News:First Service Design Firm Launches in United States 2Health News:Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market 2Health News:Florida and California Represent Equivalent Areas of Opportunity in the Alzheimer's Disease Drug Market 3
Ernest nucleus cracker extra delicate cross-action serrated paddle shaped jaws for cracking the nucleus through a 2.5 mm incision....
Epilation forceps straight ends size 3.5"....
Removal Forceps, very fine pointed tips, with textured jaws, ideal for grasping wet sutures....
Forceps, extra delicate, straight....
Medicine Products: